ライフサイエンスコーパス: Janus kinase 1

1 RS-1 renders it a poorer substrate for JAK1 (Janus kinase-1).

2 facitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional speci

3 allo-HSCT models, we show that pharmacologic Janus kinase 1/2 (JAK1/2) inhibition combined with CD45-

4 ase 2 study for the treatment of MF with the Janus kinase 1/2 (JAK1/2) inhibitor momelotinib (MMB) de

5 The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the

6 Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evol

7 agues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murin

8 a STAT3/5 inhibitor, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor.

9 Recently, several Janus kinase 1/2 (JAK1/2) inhibitors, such as ruxolitini

10 ) transcription factor and the JAK1/2-STAT3 (Janus Kinase 1/2 - Signal Transducer and Activator of Tr

11 In contrast, inhibitors of Janus kinase 1/2 and tyrosine kinase 2, as well as the I

12 evidence for the therapeutic efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in inflammatory l

13 n of STAT1 signaling with the small-molecule Janus kinase 1/2 inhibitor ruxolitinib in vitro and in v

14 Treatment with the Janus kinase 1/2 inhibitor ruxolitinib reduced hyperresp

15 Treatment with the Janus kinase 1/2 inhibitor ruxolitinib reversed STAT6 hy

16 was abrogated by ex vivo treatment with the janus kinase 1/2 inhibitor ruxolitinib.

17 Ruxolitinib is a Janus kinase 1/2 inhibitor that blocks signal transducti

18 Baricitinib is an oral selective Janus kinase 1/2 inhibitor that has achieved clinically

19 to dexamethasone and INCB018424, a selective Janus kinase 1/2 inhibitor.

20 ich was counteracted by the treatment with a Janus kinase 1/2 inhibitor.

21 efficacy and safety of baricitinib, an oral Janus kinase 1/2-selective inhibitor, versus placebo in

22 This reveals mechanistic actions of a Janus kinase-1/2 inhibitor targeting viral entry, replic

23 dogenously processed K(d)-restricted peptide Janus kinase-1(3)(5)(5)(-)(3)(6)(3) (~15,000 copies/cell

24 e shown to be mediated through activation of Janus kinase 1/3 and GATA-3.

25 The Janus kinase 1/3 inhibitor R507 is a very well-tolerated

26 The efficacy of selective Janus kinase 1/3 inhibitor R507 to prevent obliterative

27 lso evaluated the efficacy of tofacitinib (a Janus kinase 1/3 inhibitor) in 5 patients with severe, l

28 treatment with tofacitinib citrate, an oral Janus kinase 1/3 inhibitor, resulted in significant repi

29 validation of one of these candidates, Jak1 (Janus kinase 1), a tyrosine kinase of the nonreceptor ty

30 aricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheum

31 In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity

32 formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a ph

33 Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses c

34 helial cells by decreasing the expression of Janus kinase 1 and p48, two essential components of the

35 ptor and correlated with rapid and sustained Janus kinase 1 and tyrosine kinase (Tyk) 2 tyrosine phos

36 mmac-dependent signal requires activation of Janus kinases 1 and 3 and is sensitive to wortmannin, im

37 s found that IL-4-induced phosphorylation of Janus kinases 1 and 3, IL-4R alpha, signal transducer an

38 eceptor 2/beta-chain of the receptor, STAT1, Janus kinase 1, and tyrosine kinase 2.

39 so did not cause disassociation of the gp130-janus kinase-1 complex.

40 The Janus kinase-1-deficient cell line U4A expresses HLA-DR

41 TYK2-dependent IL-12 and IL-23 signaling and Janus kinase 1-dependent signaling in cells expressing t

42 inflammatory cytokines that require TYK2 and Janus kinase 1 for signal transduction.

43 nt inhibition of interleukin-6 activation of janus kinase-1, gp 130, the interleukin-6 receptor, STAT

44 e interleukin-6 signaling pathway, including janus kinase-1, gp 130, the interleukin-6 receptor, STAT

45 Finally, we determined that inhibition of Janus kinase 1, inhibition of Glycogen synthase kinase 3

46 malignancies, alone or in combination with a Janus kinase 1 inhibitor (itacitinib) or chemotherapy (r

47 We aimed to evaluate the Janus kinase 1 inhibitor itacitinib versus placebo, both

48 The TYK2/Janus kinase 1 inhibitor PF-06700841 will directly suppr

49 efficacy of multiple doses of the selective Janus kinase 1 inhibitor upadacitinib in patients with m

50 cy of itacitinib, a potent, highly selective Janus kinase 1 inhibitor with broad anti-inflammatory ac

51 nd safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, as induction and maintenance t

52 nd safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, in a randomized trial of patie

53 Abrocitinib, a Janus kinase 1 inhibitor, represents a promising therapy

54 Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerat

55 d that phosphorylation levels of IL-4Ralpha, Janus kinase 1, insulin receptor substrate 1, and insuli

56 ome (CRS), and both cytokines signal through Janus kinase 1 (JAK-1).

57 e intracellular domain of IL-4Ralpha induces Janus kinase 1 (Jak1) activation, STAT6 activation, and

58 we discovered that miR-373 directly targets Janus kinase 1 (JAK1) and IFN-regulating factor 9 (IRF9)

59 INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.

60 Furthermore, Janus kinase 1 (jak1) and Jak2 protein tyrosine kinases

61 PDGF stimulates tyrosine phosphorylation of Janus kinase 1 (JAK1) and the signal transducer and acti

62 reventing the accumulation of phosphorylated Janus kinase 1 (JAK1) and tyrosine kinase 2 (Tyk2).

63 ng the IL-4Ralpha subunit and the associated Janus kinase 1 (Jak1) as common essential components.

64 elial cell apoptosis, which was inhibited by Janus kinase 1 (JAK1) blockade.

65 f the FERM and SH2-like domains of the human Janus kinase 1 (JAK1) bound to a fragment of the intrace

66 (LKB1)-Inhibitor of Apoptosis Protein (IAP)- Janus Kinase 1 (JAK1) dynamic complex as a molecular det

67 We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti-PD

68 is required for H(2)O(2) responsiveness, and Janus kinase 1 (JAK1) is required for adequate basal sig

69 to be associated with a striking decrease in Janus kinase 1 (Jak1) levels.

70 enes encoding interferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurre

71 mutations, including activating mutations of Janus kinase 1 (JAK1), in 9.1% of patients and provides

72 ng the IL-2 receptor beta chain (IL-2Rbeta), Janus kinase 1 (Jak1), Jak3, signal transducer/activator

73 ctivators of transcription 1 (STAT1), STAT3, Janus kinase 1 (Jak1), Shc, Grb2, Sos1, and HGF receptor

74 d the proximal pathway components, including Janus kinase 1 (JAK1), tyrosine kinase 2 (Tyk2), and the

75 main-containing protein (RLTPR); moesin; and Janus kinase 1 (JAK1).

76 eron (IFN) signaling antagonist by targeting Janus kinase 1 (JAK1).

77 d revealed an interaction between DPYSL2 and Janus kinase 1 (JAK1).

78 Janus Kinase-1 (JAK1) plays key roles during neurodevelo

79 IFN-gamma alone can activate NF-kappaB, by a Janus kinase-1-mediated, but Stat1-independent, mechanis

80 nt mutations of either the Box1 motif (binds Janus kinase 1) or the signal transducer and activator o

81 and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor, for treatment of

82 irst report on the effects of abrocitinib, a Janus kinase 1-selective inhibitor, on the expression of

83 10 (IP-10), and the signaling intermediates Janus kinase 1, signal transducer and activator of trans

84 sion, which correlates with dampened AKT and Janus Kinase 1 signaling.

85 Expression of the activated form of Janus kinase 1 supported a role for IL-10 in prosurvival

86 rc, epidermal growth factor receptor (EGFR), Janus kinase 1, tyrosine kinases, and G-protein-coupled

87 mponent of IL-6 signal transduction pathway, janus kinase-1, was unchanged following either CLP or 2C